Table 1 Patient characteristics

Male, n (%)

46 (44.66)

Female, n (%)

57 (55.34)

Mean age ± SD, years (range)

66.37 ± 9.75 (43–84)

Median interval between PET and CSF, days (IQR)

41 (16–94)

PET positive, n (%)

54 (52.43)

PET negative, n (%)

49 (47.57)

 ¹¹C-PiB

67 (65.05)

 F18-Florbetaben

14 (13.59)

 F18-Florbetapir

22 (21.36)

 MCI due to AD, n (%)

44 (42.72)

  PET positive^a

27 (61.36)

  High likelihood^{a, b}

15 (34.09)

  Unlikely due to AD^a

12 (27.27)

  Conflicting/uninformative^a

17 (38.63)

   A+T-(N)-

10 (22.72)

   A+T+(N)-

2 (4.55)

   A+T+(N)+

15 (34.09)

   A+T-(N)+

0 (0)

   A-T+(N)+

5 (11.36)

   A-T+(N)-

0 (0)

   A-T-(N)+

0 (0)

   A-T-(N)-

12 (27.27)

 Mild/moderate dementia due to AD, n (%)

27 (26.21)

  PET positive^a

23 (85.19)

  High biomarker probability^a

18 (66.66)

  Uninformative^a

9 (33.33)

   A+T-(N)-

5 (18.52)

   A+T+(N)-

1 (3.70)

   A+T+(N)+

17 (62.96)

   A+T-(N)+

0 (0)

   A-T+(N)+

3 (11.11)

   A-T+(N)-

0 (0)

   A-T-(N)+

0 (0)

   A-T-(N)-

1 (3.70)

 FTLD, n (%)

17 (16.50)

  PET positive^a

2 (11.77)

  bvFTD^a

6 (35.29)

  svPPA^a

3 (17.65)

  nfvPPA^a

8 (47.06)

 Other, n^c (%)

15 (14.56)

  PET positive^a

2 (13.33)